用于定义成人急性淋巴细胞白血病风险分组的稳健且经验证的综合预后指数:一项EWALL协作研究
研究利用UKALL14、NILG-ALL10/07、GIMEMA-LAL1913和PETHEMA-ALL-HR2011四项当代学术性全国临床试验的个体患者数据,构建并验证基于白细胞计数、遗传学和诱导结束微小残留病的EWALL预后指数(EWALL-PI)。对778例15至67岁完全缓解患者计算风险评分,分析显示EWALL-PI与复发和死亡相关,每增加1个单位复发或死亡风险增加约30%,且风险模型优于各试验所用分层算法。阈值分析确定EWALL-PI<2.50为标准风险、≥2.50为高风险,高风险患者复发率显著增加且生存较差。
要点
- EWALL-PI整合白细胞计数、遗传学和诱导结束微小残留病,在4项独立成人ALL临床试验中验证。
- EWALL-PI每增加1个单位,复发或死亡风险增加约30%,未见试验间或亚组间异质性证据。
- EWALL-PI<2.50为标准风险、≥2.50为高风险,高风险患者复发率显著增加且生存较差。
核心结论
- 在4项独立成人ALL临床试验中验证了一个综合风险模型,证明其可用于定义临床相关风险分组。
研究设计与样本
- 研究使用UKALL14、NILG-ALL10/07、GIMEMA-LAL1913和PETHEMA-ALL-HR2011四项当代学术性全国临床试验的个体患者数据,生成并验证EWALL-PI。
- 对778例15至67岁完全缓解患者,使用经验证的UKALL-PI公式并作轻微修改以反映儿童与成人ALL差异,计算个体风险评分。
主要发现
- 逐试验分析显示EWALL-PI与复发和死亡相关。
- 回归分析显示EWALL-PI每增加1个单位,复发或死亡风险增加约30%,未见试验间或患者亚组间异质性证据。
- EWALL-PI定义的风险模型优于各试验使用的分层算法。
- 阈值分析确定EWALL-PI<2.50为B细胞和T细胞患者的标准风险组、≥2.50为高风险组。
- 逐试验分析显示高风险患者较标准风险患者复发率显著增加且生存较差(复发亚分布风险比范围1.85至3.28;死亡风险比范围1.73至3.03)。
关键数值与推荐
- EWALL-PI标准风险组为EWALL-PI<2.50,高风险组为EWALL-PI≥2.50。
- 高风险组较标准风险组的复发亚分布风险比范围为1.85至3.28,死亡风险比范围为1.73至3.03。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Risk stratification is crucial to the successful treatment of acute lymphoblastic leukemia (ALL). Although numerous risk factors have been identified, an optimal prognostic model for integrating variables has not been developed. We used individual patient data from 4 contemporary academic national clinical trials, UKALL14, NILG-ALL10/07, GIMEMA-LAL1913, and PETHEMA-ALL-HR2011, to generate and validate the European Working Group for Adult ALL prognostic index (EWALL-PI), which is based on white blood cell count, genetics, and end of induction minimal residual disease (MRD). Individual patient risk scores were calculated for 778 patients aged 15 to 67 years in complete remission using the validated UKALL-PI formula, applying minor modifications to reflect differences between pediatric and adult ALL. Per-trial analysis revealed that EWALL-PI correlated with relapse and death. Regression analysis revealed that each unit increase in EWALL-PI increased the risk of relapse or death by ∼30% with no evidence of heterogeneity across trials or patient subgroups. EWALL-PI-defined risk models outperformed the stratification algorithms used by each trial. Threshold analysis revealed an EWALL-PI threshold that divided patients with B cell and T cell into standard (EWALL-PI <2.50) and high (EWALL-PI ≥2.50) risk groups, respectively. Per-trial analysis showed that patients at high risk had a significantly increased relapse rate and inferior survival compared with patients with standard risk (subdistribution hazard ratio for relapse, ranged from 1.85 to 3.28; hazard ratio for death, 1.73 to 3.03). Subgroup analysis confirmed the robustness of these risk groups by sex, age, white blood cell count, and lineage. In conclusion, we validated an integrated risk model across 4 independent adult ALL clinical trials, demonstrating its utility defining clinically relevant risk groups.
引用
- Enshaei A, Joy M, Butler E, et al. A robust and validated integrated prognostic index for defining risk groups in adult acute lymphoblastic leukemia: an EWALL collaborative study. Blood Adv. 2024. PMID: 38113467. doi:10.1182/bloodadvances.2023011661
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。